Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology <scp>W</scp> orking <scp>G</scp> roup on <scp>M</scp> yocardial and <scp>P</scp> ericardial <scp>D</scp> iseases

Pablo García‐Pavía(Universidad Francisco de Vitoria), Aleš Linhart(Charles University), Claudio Rapezzi(Boston University), Urs Eriksson(University of Zurich), Ingrid Kindermann(Baker Heart and Diabetes Institute), Michael Arad(Tel Aviv University), Sabine Pankuweit(Universitätsklinikum Gießen und Marburg), Marianna Fontana(Johnson & Johnson (United States)), Massimo Imazio, Alida L.P. Caforio(University of Padua), Julian D. Gillmore(Alnylam Pharmaceuticals (United States)), Matthew J. Maurer(Boston University), Stéphane Heymans(Maastricht University), Yehuda Adler, Arnt V. Kristen(Université Paris-Sud), Thibaud Damy(Amyloidosis Foundation), Martha Grogan(Boston University), Cristina Basso(University of Padua), Esther González-López(Children's Cancer and Leukaemia Group), Giampaolo Merlini(University of Pavia), Ivana Burazor(University of Belgrade), Angelos G. Rigopoulos(Luther University), Antonis Pantazis(Harefield Hospital), Antonio Brucato(Azienda Ospedaliera Fatebenefratelli e Oftalmico)
European Journal of Heart Failure
April 1, 2021
Cited by 330


Related Papers